|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Shriners Hospitals for Children |
|---|---|
| Information provided by: | Shriners Hospitals for Children |
| ClinicalTrials.gov Identifier: | NCT00250081 |
Purpose
Doctors use different treatments for people with Cerebral Palsy. Surgery is one option. Botulinum toxin injections are another option; these are given directly into spastic muscles to weaken them temporarily. Regular ongoing treatment (splinting, stretching and exercises) is another option. The investigators want to find out if surgery works better than Botulinum Toxin (Botox) injections or regular ongoing treatment (therapy), and if the effects of Botulinum Toxin injections last for longer than six months.
| Condition | Intervention |
|---|---|
|
Cerebral Palsy |
Procedure: Upper Extremity Tendon transfer Procedure: Botulinum Toxin injections in Upper Extremity Procedure: Regulalry ongoing therapy |
| Study Type: | Interventional |
| Study Design: | Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | Multi Center Project: Comparison of Functional Outcomes of Tendon Transfer Surgery, Botulinum Toxin Injections and Regular Ongoing Treatment in Hemiplegic Upper Extremity Cerebral Palsy |
| Estimated Enrollment: | 100 |
| Study Start Date: | February 2005 |
| Estimated Study Completion Date: | December 2008 |
| Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
The specific aims of this study and the methodology for achieving them are:
Botulinum toxin has been shown to have beneficial effects on UE function while the muscles injected remain weakened by the toxin. Clinicians have theorized that improvements in UE function are maintained after the toxin wears off, but this has not been proven. Children randomized to the Botulinum toxin injection group will receive 3 injections. Their function will be tested before the first injection, while the paralytic results of the second injection are still in effect, and after the paralytic effects of the third injection have worn off, and the results compared in order to determine if functional improvements outlast the medicinal effects.
Eligibility| Ages Eligible for Study: | 5 Years to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Michelle James, MD | 916-453-2049 | mjames@shrinenet.org |
| Contact: Anita Bagley, PhD | 916-453-2280 | abagley@shrinenet.org |
| United States, California | |
| Shriners Hospitals for Children, Northern California | Recruiting |
| Sacramento, California, United States, 95817 | |
| Contact: Susan Anderson 916-453-2131 sanderson@shrinenet.org | |
| Principal Investigator: Michelle James, MD | |
| Sub-Investigator: Anita Bagley, PhD | |
| United States, Florida | |
| Shriners Hosptials for Children | Recruiting |
| Tampa, Florida, United States, 33612 | |
| Contact: Adrienne Karol, OTRL 813-972-2250 akarol@shrinenet.org | |
| Principal Investigator: Alfred Hess, MD | |
| United States, Louisiana | |
| Shriners Hospitals for Children | Recruiting |
| Shreveport, Louisiana, United States, 71103 | |
| Contact: Anne Boyd, LOTR 318-222-5704 aboyd@shrinenet.org | |
| Contact: Jeanie McGee 318-222-5704 jmcgee@shrinenet.org | |
| Principal Investigator: Phillip Gates, MD | |
| United States, Minnesota | |
| Shriners Hospitals for Children, Twin Cities | Recruiting |
| Minneapolis, Minnesota, United States, 55414 | |
| Contact: Wendy Tomhave, OTR 612-596-6100 wtomhave@shrinenet.org | |
| Principal Investigator: Ann Van Heest, MD | |
| United States, Missouri | |
| Shriners Hospital for Children | Not yet recruiting |
| St. Louis, Missouri, United States, 63131 | |
| Contact: Loray Dailey, OTR 314-432-3600 ldailey@shrinenet.org | |
| Principal Investigator: Paul Manske, MD | |
| United States, South Carolina | |
| Shriners Hospitals for Children | Recruiting |
| Greenville, South Carolina, United States, 29605 | |
| Contact: Lisa Wagner, OTR 864-271-3444 lwagner@shrinenet.org | |
| Contact: Laura Peace, OTR 864-271-3444 lpeace@shrinenet.org | |
| Principal Investigator: Jon Davids, MD | |
| United States, Utah | |
| Shriners Hosptials for Children, Intermountain | Recruiting |
| Salt Lake City, Utah, United States, 84103 | |
| Contact: Barbara Johnson, PT 801-536-3500 bjohnson@shrinenet.org | |
| Contact: Bruce McWilliams, PhD 801-536-3500 | |
| Principal Investigator: Douglas Hutchinson, MD | |
| United States, Virginia | |
| Kluge Childrens Rehabilitation Hospital | Not yet recruiting |
| Charlottesville, Virginia, United States, 22903 | |
| Contact: Walter Farrell, OTR/L WF9S@hscmail.mcc.virginia.edu] | |
| Principal Investigator: Mark Abel, MD | |
| Canada, Quebec | |
| Shriners Hosptial for Children | Recruiting |
| Montreal, Quebec, Canada | |
| Contact: Nathalie Bilodeau, OTRL 514-842-4464 nbilodeau@shrinenet.org | |
| Principal Investigator: Chantal Janelle, MD | |
| Principal Investigator: | Michelle James, MD | Shriners Hospitals for Children, Northern Calfiornia |
| Principal Investigator: | Ann Van Heest, MD | Shriners Hospitals for Children, Twin Cities |
| Principal Investigator: | Anita Bagley, PhD | Shriners Hospitals for Children, Northern California |
More Information
| Responsible Party: | Shriners Hospital for Children, Northern California ( Michelle James, MD ) |
| Study ID Numbers: | 9196-200513113 |
| Study First Received: | November 3, 2005 |
| Last Updated: | September 5, 2008 |
| ClinicalTrials.gov Identifier: | NCT00250081 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Cerebral Palsy Tendon Transfer Botulinium Toxin Type A Occupational Therapy Child |
|
Anti-Dyskinesia Agents Brain Damage, Chronic Nervous System Diseases Central Nervous System Diseases Brain Diseases Pharmacologic Actions Paralysis |
Signs and Symptoms Cerebral Palsy Botulinum Toxins Therapeutic Uses Neurologic Manifestations Central Nervous System Agents |